In an era plagued by antibiotic resistance, a groundbreaking initiative is emerging from a Harvard health startup aimed at revolutionizing our approach to combating drug-resistant infections.This new class of antibiotics promises to address the dire need for effective treatments in a landscape where traditional medicines fail.